Prosecution Insights
Prosecution Insights
6 pending office actions • 2 clients • 6 examiners • 6 art units • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| §102 only | 1 (17%) |
| §112 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| No statute on record | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKINSON, PAUL W | 1 | 63.0% | +9.5% |
| CORDAS, EMILY ANN | 1 | 50.6% | +58.5% |
| CRAIGO, WILLIAM A | 1 | 49.3% | +38.7% |
| ROGERS, ERIC JASON | 1 | 59.2% | +28.6% |
| BATES, KEENAN ALEXANDER | 1 | 46.3% | +70.8% |
| NGUYEN, NGHI V | 1 | 53.6% | +50.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18138904 | ENCAPSULATION OF PANCREATIC CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | CRAIGO, WILLIAM A | 105d overdue |
| 17560680 | ENHANCED DIFFERENTIATION OF BETA CELLS | NGUYEN, NGHI V | 86d overdue |
| 17669874 | PANCREATIC DIFFERENTIATION | BATES, KEENAN ALEXANDER | 37d overdue |
| 18018787 | IN VITRO DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | ROGERS, ERIC JASON | 28d |
| 18281154 | STEM CELL DIFFERENTIATION AND POLYMERS | CORDAS, EMILY ANN | 71d |
| Client (Assignee) | Pending OAs |
|---|---|
| Vertex | 5 |
| ViaCyte, Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 1632 | 1 |
| 1615 | 1 |
| 1638 | 1 |
| 1631 | 1 |
| 1653 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18647137 | STEM CELL DERIVED PANCREATIC ISLET DIFFERENTIATION | Vertex Pharmaceuticals Incorporated | DICKINSON, PAUL W | 1618 | §103 | Non-Final OA | 26d overdue | Pending | Apr 26, 2024 |
| 18281154 | STEM CELL DIFFERENTIATION AND POLYMERS | Vertex Pharmaceuticals Incorporated | CORDAS, EMILY ANN | 1632 | DPOther | Non-Final OA | 71d | Pending | Sep 08, 2023 |
| 18138904 | ENCAPSULATION OF PANCREATIC CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | Viacyte, Inc. | CRAIGO, WILLIAM A | 1615 | Other | Non-Final OA | 105d overdue | Pending | Apr 25, 2023 |
| 18018787 | IN VITRO DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | Vertex Pharmaceuticals Incorporated | ROGERS, ERIC JASON | 1638 | §102 | Non-Final OA | 28d | Pending | Jan 30, 2023 |
| 17669874 | PANCREATIC DIFFERENTIATION | Vertex Pharmaceuticals Incorporated | BATES, KEENAN ALEXANDER | 1631 | §112 | Final Rejection | 37d overdue | Pending | Feb 11, 2022 |
| 17560680 | ENHANCED DIFFERENTIATION OF BETA CELLS | Vertex Pharmaceuticals Incorporated | NGUYEN, NGHI V | 1653 | §103 | Non-Final OA | 86d overdue | Pending | Dec 23, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial